Answers are grounded in this paper and cite their sources.
The 1990s have seen a resurgence of interest in psychopharmacology. This has coincided with new medicines marketed for the treatment of neurological or mental health problems. There are new medicines for the treatment of depression, schizophrenia, Alzheimer's disease and epilepsy, all of which could have value for people with mental retardation.
No takes yet. Share an insight, caveat, or question.
David Branford (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: